7Baggers
 BioVie to Host Live Investor Webinar and Q&A on Oct. 8  GlobeNewswire Fri, 26 Sep 2025 12:02:06 GMT
 How to contact the Daily Bulletin  FinancialContent Thu, 25 Sep 2025 13:07:25 GMT
 How to contact the Daily Bulletin  FinancialContent Tue, 23 Sep 2025 03:46:23 GMT
 silicon valley  FinancialContent Sun, 07 Sep 2025 20:26:00 GMT
 published on: 2025-08-31 20:53:58  Newser Mon, 01 Sep 2025 01:53:58 GMT
 published on: 2025-08-30 21:03:09  Newser Sun, 31 Aug 2025 02:03:09 GMT
 published on: 2025-08-29 16:04:21  Newser Fri, 29 Aug 2025 21:04:21 GMT
 published on: 2025-08-29 11:30:01  Newser Fri, 29 Aug 2025 16:30:01 GMT
 published on: 2025-08-29 05:11:43  Newser Fri, 29 Aug 2025 10:11:43 GMT
 published on: 2025-08-29 03:46:03  Newser Fri, 29 Aug 2025 08:46:03 GMT
 biovie price target adjusted to $12 from $6 at brookline  TipRanks Fri, 29 Aug 2025 07:00:00 GMT

BioVie Inc
(NASDAQ:BIVI) 

BIVI stock logo

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly...

Founded: 2013
Full Time Employees: 2
CEO: Terren S. Peizer  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends